EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers

Srijita Chatterjee, Swati Arya iD, Nidhi Sharma, Madhuri Grover, Divya Yadav, Hiba Parveen

Medical Oncology · 2026

DOI: 10.1007/s12032-026-03392-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Oncology, 2026. Verfasst von Srijita Chatterjee und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Balawala, Dehradun, Uttarakhand, 248001, India. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Neoplasms, Antineoplastic Agents, Oncogene Protein p21(ras). Die Arbeit nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the most commonly mutated oncogenes is Kirsten rat sarcoma viral oncogene homolog (KRAS, which is found in nearly all pancreatic ductal adenocarcinomas (PDAC), is commonly found in colorectal cancers (CRC), and is found in significant numbers in non-small-cell lung cancers (NSCLC). For most of its history, KRAS has been regarded as “undruggable.” Still, with recent developments in covalent inhibitors targeting KRAS^G12C, specifically sotorasib and adagrasib, it has now been validated as a viable therapeutic target. Unfortunately, most KRAS mutations occur outside KRAS^G12C and thus require alternative therapeutic strategies beyond those already available. This review summarizes the fast-moving developments in the world of allele-specific and pan-KRAS inhibitors with reference to patent filings, clinical trials, and combinations with other agents. New classes of KRAS inhibitors have recently emerged, including non-covalent inhibitors (MRTX1133, RMC-9805), pan-RAS (ON) antagonists (RMC-6236), and KRAS-directed degraders (ASP3082), as well as planned rational combinations of these new KRAS inhibitors with agents targeting SHP2, SOS1, MEK, and immune checkpoint inhibitors. Other factors, including the development of innovative drug delivery systems, the exploration of resistance mechanisms, and the pursuit of synthetic lethality, could facilitate the complexity of treating KRAS-driven cancers. The regulatory environment and commercialization efforts present opportunities and challenges for precision oncology in KRAS-driven cancers globally. Overall, the rapid evolution of KRAS-targeted therapeutic agents represents a shift from allele-specific inhibition towards a strategy that is mutation/context-dependent, thereby creating further clinical translation opportunities and increased patient benefit. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)NeoplasmsAntineoplastic AgentsOncogene Protein p21(ras)HumansMutationMolecular Targeted TherapyPatents as TopicAnimals

Stichwörter der Autor:innen

CancerKRAS inhibitorsOncogenePatentsTranslational opportunities

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic AgentsOncogene Protein p21(ras)

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Balawala, Dehradun, Uttarakhand, 248001, India.
  • School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Balawala, Dehradun, Uttarakhand, 248001, India. aryaswati2020@gmail.com.
  • Department of Pharmacy, School of Medical & Allied Sciences, GD Goenka University, Haryana, 122103, India.
  • School of Medical & Allied Sciences, K.R. Mangalam University, Gurugram, Haryana, 122103, India.
  • SGT College of Pharmacy, SGT University, Gurugram, Haryana, 122505, India.
  • Faculty of Pharmacy, Veer Madho Singh Bhandari, Uttarakhand Technical University, Suddhowala, Dehradun, Uttarakhand, 248009, India.

ORCID-Profile: Swati Arya

Zitieren

APA

Chatterjee, S., Arya, S., Sharma, N., Grover, M., Yadav, D., & Parveen, H. (2026). Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. Medical Oncology. https://doi.org/10.1007/s12032-026-03392-6

Vancouver

Chatterjee S, Arya S, Sharma N, Grover M, Yadav D, Parveen H. Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. Medical Oncology. 2026. doi:10.1007/s12032-026-03392-6

BibTeX
@article{Chatterjee2026,
  author = {Chatterjee, Srijita and Arya, Swati and Sharma, Nidhi and Grover, Madhuri and Yadav, Divya and Parveen, Hiba},
  title = {Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers},
  journal = {Medical Oncology},
  year = {2026},
  doi = {10.1007/s12032-026-03392-6}
}
Kostenlos starten →